784150-40-9

Basic information

• Product Name: 6-broMo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyriMidine
• Synonyms: 6-broMo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyriMidine;7H-Pyrrolo[2,3-d]pyriMidine, 6-broMo-4-chloro-7-(phenylsulfonyl)-;7-(benzenesulfonyl)-6-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine
• CAS NO: 784150-40-9
• Molecular Formula: C₁₂H₇BrClN₃O₂S
• Molecular Weight: 372.62488
• EINECS: -0
• Mol File: 784150-40-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-broMo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-broMo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyriMidine(784150-40-9)
• EPA Substance Registry System: 6-broMo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyriMidine(784150-40-9)

Safety Data

• Hazardous Substances Data: 784150-40-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
6-Bromo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine is used as a starting material for the design and synthesis of new pharmaceutical agents. Its diverse functional groups and chemical reactivity make it a promising candidate for the development of novel drugs.
Used in Chemical Synthesis:
In the chemical industry, 6-Bromo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine is used as an intermediate in the synthesis of more complex molecules. Its unique structure and functional groups allow for a wide range of chemical reactions, facilitating the creation of new compounds with potential applications in various sectors.
Used in Material Science:
6-Bromo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine may also find applications in material science, where its chemical properties could be harnessed to develop new materials with specific characteristics. 6-broMo-4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyriMidine's potential use in this field would depend on further research and development to explore its properties and possible applications.

Upstream product

• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 98-09-9 benzenesulfonyl chloride 
• 630-25-1 1,2-dibromo-1,1,2,2-tetrachloroethane 
• 186519-89-1 7-(benzenesulfonyl)-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 784150-41-0 6-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 1351091-54-7 N-methyl-3-{[6-(2-methylphenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzenesulfonamide 
• 1351091-73-0 N-methyl-3-{[6-(3-methylphenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzenesulfonamide 
• 1351091-71-8 N-methyl-3-{[6-(4-methylphenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzenesulfonamide 
• 1351091-57-0 N-methyl-3-({6-[3-(trifluoromethyl)phenyl]-1H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)benzenesulfonamide 
• 1351091-44-5 3-[(6-bromo-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-4-(dimethylamino)-N-methylbenzenesulfonamide 

Relevant articles and documents

The condensed heterocyclic compound such as Bruton kinase inhibitors (by machine translation)

The invention relates to a fused heterocycle derivative and an application, which has a structure shown in a formula 1). The compound with the structure shown in the formula 1) has good inhibition effect to Bruton kinases activity, and median inhibitory concentration is lower than 10mol.L generally.

Identification of Purines and 7-Deazapurines as Potent and Selective Type i Inhibitors of Troponin I-Interacting Kinase (TNNI3K)

A series of cardiac troponin I-interacting kinase (TNNI3K) inhibitors arising from 3-((9H-purin-6-yl)amino)-N-methyl-benzenesulfonamide (1) is disclosed along with fundamental structure-function relationships that delineate the role of each element of 1 for TNNI3K recognition. An X-ray structure of 1 bound to TNNI3K confirmed its Type I binding mode and is used to rationalize the structure-activity relationship and employed to design potent, selective, and orally bioavailable TNNI3K inhibitors. Identification of the 7-deazapurine heterocycle as a superior template (vs purine) and its elaboration by introduction of C4-benzenesulfonamide and C7- and C8-7-deazapurine substituents produced compounds with substantial improvements in potency (>1000-fold), general kinase selectivity (10-fold improvement), and pharmacokinetic properties (>10-fold increase in poDNAUC). Optimal members of the series have properties suitable for use in in vitro and in vivo experiments aimed at elucidating the role of TNNI3K in cardiac biology and serve as leads for developing novel heart failure medicines.

SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS

The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

COMPOUNDS AND METHODS

Disclosed are compounds having the Formula (I), wherein X, Y, Z, R1, R2 and R3 are as defined herein, and methods of making and using the same.

Efficient formation of 4,6-disubstituted pyrrolo[2,3-d]pyrimidines: A novel route to TWS119, a glycogen synthase kinase-3β inhibitor

A concise synthesis of 4,6-disubstituted pyrrolo[2,3-d]pyrimidines is described. The key step involves the formation of an ether or thioether linkage along with concurrent ring closure in one-pot to yield the desired product in only two steps from a common intermediate. The reaction is chemoselective to incorporate phenol, thiophenol, and thiol. This method enabled efficient production of TWS119, a glycogen synthase kinase-3β inhibitor.

Heterocyclic Compounds Useful as RAF Kinase Inhibitors

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.